Dare Bioscience, Inc. Finance Lease, Right-of-Use Asset, after Accumulated Amortization
Dare Bioscience, Inc. (DARE) had Finance Lease, Right-of-Use Asset, after Accumulated Amortization of $872.39 thousand as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:FinanceLeaseRightOfUseAsset · last filed 2026-08-13
- 2026-06-30: Finance Lease, Right-of-Use Asset, after Accumulated Amortization $872.39K.
- 2026-03-31: Finance Lease, Right-of-Use Asset, after Accumulated Amortization $1.31M.
- 2025-12-31: Finance Lease, Right-of-Use Asset, after Accumulated Amortization $1.74M.
- 2025-09-30: Finance Lease, Right-of-Use Asset, after Accumulated Amortization $2.24M.
| Period end | Finance Lease, Right-of-Use Asset, after Accumulated Amortization |
|---|---|
| 2026-06-30 | $872.39K 10-Q · filed 2026-08-13 |
| 2026-03-31 | $1.31M 10-Q · filed 2026-05-14 |
| 2025-12-31 | $1.74M 10-Q · filed 2026-08-13 |
| 2025-09-30 | $2.24M 10-Q · filed 2025-11-13 |
| 2025-06-30 | $2.70M 10-Q · filed 2025-08-14 |
| 2025-03-31 | $3.15M 10-Q · filed 2025-05-13 |
| 2024-12-31 | $0.00 10-K · filed 2026-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |